Merck Hepatitis C Drug to Enter Crowded Field With High Prices

  • FDA approves drug that will compete against Gilead, AbbVie
  • Agency says Merck drug approved for genotypes 1 and 4

Merck & Co.’s new hepatitis C drug was approved for use in adult patients with genotype 1 and 4 infections, pitting it against high-priced therapies from Gilead Sciences Inc. and AbbVie Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.